DK2091520T3 - Oral doseringsform omfattende trisubstituerede glycerol-forbindelser - Google Patents

Oral doseringsform omfattende trisubstituerede glycerol-forbindelser

Info

Publication number
DK2091520T3
DK2091520T3 DK07822468.0T DK07822468T DK2091520T3 DK 2091520 T3 DK2091520 T3 DK 2091520T3 DK 07822468 T DK07822468 T DK 07822468T DK 2091520 T3 DK2091520 T3 DK 2091520T3
Authority
DK
Denmark
Prior art keywords
dosage form
oral dosage
form containing
glycerol compounds
containing trisubstituted
Prior art date
Application number
DK07822468.0T
Other languages
Danish (da)
English (en)
Inventor
Wolfgang Richter
Lutz Weber
Original Assignee
Alphaptose Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphaptose Gmbh filed Critical Alphaptose Gmbh
Application granted granted Critical
Publication of DK2091520T3 publication Critical patent/DK2091520T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07822468.0T 2006-11-10 2007-11-09 Oral doseringsform omfattende trisubstituerede glycerol-forbindelser DK2091520T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85815706P 2006-11-10 2006-11-10
PCT/EP2007/062180 WO2008055996A1 (en) 2006-11-10 2007-11-09 Oral dosage form comprising tri-substituted glycerol compounds

Publications (1)

Publication Number Publication Date
DK2091520T3 true DK2091520T3 (da) 2012-06-18

Family

ID=39092201

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07822468.0T DK2091520T3 (da) 2006-11-10 2007-11-09 Oral doseringsform omfattende trisubstituerede glycerol-forbindelser

Country Status (11)

Country Link
US (2) US20110110984A1 (enExample)
EP (1) EP2091520B1 (enExample)
JP (1) JP5352466B2 (enExample)
CN (2) CN101610758A (enExample)
AT (1) ATE546133T1 (enExample)
AU (1) AU2007316588B2 (enExample)
CA (1) CA2668919C (enExample)
DK (1) DK2091520T3 (enExample)
ES (1) ES2382756T3 (enExample)
RU (1) RU2009121838A (enExample)
WO (1) WO2008055996A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
WO2008074572A1 (en) * 2006-12-20 2008-06-26 Universitätsklinikum Hamburg-Eppendorf Use of tri-substituted glycerol compounds for the treatment of hematological malignancies
EP1952803A1 (en) * 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2619686C2 (de) 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
DE3918082A1 (de) 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
DE4000084A1 (de) 1990-01-03 1991-07-04 Medmark Pharma Gmbh Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts)
WO1999030690A1 (en) * 1997-12-15 1999-06-24 Axia Therapeutics, Inc. Oral delivery formulation
DE19822509A1 (de) * 1998-05-19 1999-11-25 Medmark Pharma Gmbh Edelfosin zur Behandlung von Hirntumoren
DE19829448A1 (de) 1998-07-01 2000-10-12 Medmark Pharma Gmbh 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
JP2002532553A (ja) * 1998-12-21 2002-10-02 インケイサ．ソシエダ アノニマ 有害な胃腸副作用を引き起こさない有力な抗炎症剤としてのエーテルリゾリン脂質の使用
JP2005517690A (ja) * 2002-02-01 2005-06-16 ファイザー・プロダクツ・インク 固体薬物分散物を含有する即時放出剤形
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide

Also Published As

Publication number Publication date
ES2382756T3 (es) 2012-06-13
EP2091520B1 (en) 2012-02-22
US20170157150A1 (en) 2017-06-08
CA2668919A1 (en) 2008-05-15
WO2008055996A1 (en) 2008-05-15
AU2007316588A1 (en) 2008-05-15
ATE546133T1 (de) 2012-03-15
AU2007316588B2 (en) 2013-11-21
CN103816127A (zh) 2014-05-28
CN101610758A (zh) 2009-12-23
EP2091520A1 (en) 2009-08-26
CA2668919C (en) 2015-11-03
JP2010509293A (ja) 2010-03-25
RU2009121838A (ru) 2010-12-20
JP5352466B2 (ja) 2013-11-27
US20110110984A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2013012588A (es) Inhibidores de cinasa.
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
WO2011047173A3 (en) Pharmaceutical compositions for oral administration
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
RU2013148627A (ru) Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии
MA32719B1 (fr) Formulations galeniques de composes organiques